Adverse effects of antiretroviral treatment

Indian Journal of Dermatology, Venereology and Leprology

Volumn 74, Issue 3, 2008, Pages 234-237

  Sharma, Ajay ^a   Vora, Roshni ^a   Modi, Megha ^a   Sharma, Archana ^a   Marfatia, Yogesh ^a  

^a Baroda Medical College   (India)

Author keywords

Acquired immune deficiency syndrome; Adverse drug reaction; Antiretroviral therapy; Human immune deficiency virus

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ABDOMINAL PAIN; ANEMIA; ANOREXIA; ARTICLE; DIARRHEA; DIZZINESS; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATTY LIVER; GASTRITIS; HAIR LOSS; HEADACHE; HERPES SIMPLEX; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; HYPERLIPIDEMIA; HYPERPIGMENTATION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; LACTIC ACIDEMIA; LEUKOPENIA; LIPODYSTROPHY; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MEGALOCYTOSIS; MITOCHONDRIAL TOXICITY; MOLLUSCUM CONTAGIOSUM; MOUTH DISEASE; NAIL PIGMENTATION; NAUSEA; PANCREATITIS; PARONYCHIA; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRURITUS; RASH; SIDE EFFECT; SKIN ALLERGY; SLEEP DISORDER; STEATOSIS; TUBERCULOSIS; TUBERCULOUS LYMPHADENITIS; URTICARIA; VIRUS INFECTION; VIVID DREAM; VOMITING;

EID: 46349108423     PISSN: 03786323     EISSN: None     Source Type: Journal    
DOI: 10.4103/0378-6323.41368     Document Type: Article

References (9)

1. d'Arminio Monforte A, Lepri AC, Rezza G, Pezzoti P, Antinori A, Phillips AN, et al. Insights into the reasons for discontinuation of the first highly active antretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients: Italian cohort of antiretroviral Naïve patients. AIDS 2000;14:499-507.
2. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999;131:81-7.
3. Divisions of AIDS Table for Grading Severity of Adult Adverse experiences. AIDS Clinical Trial Group Protocol Management Handbook. Divisions of AIDS (DAIDS) Regulatory Operations Center (ROC) Titled Serious Adverse Experience (SAE) Reporting Manual for: AIDS Clinical Trail Groups (AACTG and PACTG), Community Programs for Clinical Research on AIDS (CPCRA), Intramural Research Programs (IRP). Rockville, MD: Frontier Science, 1 August 1998.
4. Fellay J, Bousaker K, Ledergerber B, Bernasconi E, Furrer H, Battegay M, et al. Prevalence of adverse drug events associated with potent antiretroviral treatment: Swiss HIV cohort study. Lancet 2001;358:1322-7.
5. Kumarasamy MP, Balakrishnan. Safety, tolerability and effectiveness of locally produced generic antiretroviral drugs in persons with HIV disease in Southern India. Int Cong Drug Ther HIV 2002;6:298.
6. Van Leeuwen R, Van den Hurk PJ, Jobsis GJ. Failure to maintain high dose treatment regimens during long term use Zidovudine in patients with symptomatic HIV-1 infections. Genitourin Med 1990;66:418-22.
7. Saint-Marc T, Partisani M, Poizot-Martin I, Bruno F, Rouviere O, Lang JM, et al. A syndrome of peripheral fat wasting (Lipodystrophy) in patients receiving long term nucleoside analogue therapy. AIDS 1999;13:1659-67.
8. O'Brien ME, Clark RA, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in urban outpatient cohort. J Acquir Immune Defic Syndr 2003;34:407-14.
9. Maniar J, Desai S. Antiretroviral therapy: Real challenges for developing World. Int Cong Drug Ther HIV 2000;5:249.